Zerumbone Induces Cytotoxicity and Inhibits Cell Migration of Human Colon Cancer Cells

(Terumbon Mengaruh Kesitotoksikan dan Merencat Penghijrah Sel pada Sel Kanser Kolon Manusia)

TAN MIN JIEN, SITI NUR PARVIN AB HAMID, NUR FARIESHA MD HASHIM, NURDIN ARMANIA, HASNI IDAYU SAIDI & NORAINA MUHAMAD ZAKUAN*

INTRODUCTION

Colon cancer is the second leading cause of cancer death among males and females. Survival in colorectal cancer patients is poor and greatly affected by its metastasis. Zerumbone (ZER) is an active compound isolated from the essential volatile oil of an edible ginger plant, Zingiber zerumbet. It is known to exhibit anticancer properties which able to inhibit cancer cell proliferation and induce apoptosis in colon cancer. These findings led us to investigate the ability of ZER to inhibit cell migration in colon cancer cell line. From the MTT results, the IC_{50} values for HCT116 cells treated with ZER were 8.9 ± 0.3, 18.0 ± 1.2, and 21.3 ± 3.5 µg/mL at 24, 48, and 72 h of incubation, respectively. The results show that the IC_{50} was significantly increased (p <0.05) in a time-dependent manner. The treatment of ZER at higher concentration (6 and 9 µg/mL) inhibited the migration of HCT116 cells at 1.5-fold higher compared to that of the untreated cells which reduced in the scratch gap. The characteristic of apoptosis such as cell shrinkage, membrane blabbing, and detachment of cells were observed on HCT116 cells treated with ZER, suggesting that the mode cell death induced by ZER on HCT116 cells might be due to apoptosis. Hence, it is concluded that ZER exhibits cytotoxic effects and inhibits cell migration in colon cancer cells.

Keywords: Colon cancer; metastasis; migration; Zerumbone

ABSTRACT

Colorectal cancer is the second leading cause of cancer death among males and females. Survival in colorectal cancer patients is poor and greatly affected by its metastasis. Zerumbone (ZER) is an active compound isolated from the essential volatile oil of an edible ginger plant, Zingiber zerumbet. It is known to exhibit anticancer properties which can inhibit cancer cell proliferation and induce apoptosis in colon cancer. These findings led us to investigate the ability of ZER to inhibit cell migration in colon cancer cell line. From the MTT results, the IC_{50} values for HCT116 cells treated with ZER were 8.9 ± 0.3, 18.0 ± 1.2, and 21.3 ± 3.5 µg/mL at 24, 48, and 72 h of incubation, respectively. The results show that the IC_{50} was significantly increased (p <0.05) in a time-dependent manner. The treatment of ZER at higher concentration (6 and 9 µg/mL) inhibited the migration of HCT116 cells at 1.5-fold higher compared to that of the untreated cells which reduced in the scratch gap. The characteristic of apoptosis such as cell shrinkage, membrane blabbing, and detachment of cells were observed on HCT116 cells treated with ZER, suggesting that the mode cell death induced by ZER on HCT116 cells might be due to apoptosis. Hence, it is concluded that ZER exhibits cytotoxic effects and inhibits cell migration in colon cancer cells.

Keywords: Colon cancer; metastasis; migration; Zerumbone

INTRODUCTION

Cancer metastasis is the major cause of fatality which occurs in approximately 60% of colon cancer patients (Siegel et al. 2017). Although the 5-year survival rate for early stage colon cancer patients is up to 90%, the 5-year survival rate for metastatic state greatly reduced to 13.9% of patients (Vassos & Piso 2018). In colon cancer, liver is the most common site of metastasis (Alhumaid et al. 2018). It has been reported that approximately 30% of all colon cancer patients have liver metastases which
accounted for two-third of the deaths (Abdalla et al. 2006).

The current available modalities for metastatic colon cancer treatment include surgical resection (Alhumaid et al. 2018) and chemotherapy such as fluorouracil (addition with oxaliplatin and irinotecan) (Cheng et al. 2013). However, the management and treatment of metastasis cancer are still a major challenge because of the lack of understanding on its molecular pathway (Alhumaid et al. 2018).

Despite the availability of many current improved therapies, this study focuses on the utilisation of natural product-derived active compounds, i.e. Zerumbone (ZER) to treat metastasis cancer. ZER is a cyclic sesquiterpene from the rhizomes of an edible ginger plant, Zingiber zerumbet (L.) Smith (originated from Southeast Asia) (Deorukhkar et al. 2015), well known for its potential anticancer properties.

Several studies have proven that ZER inhibits cell proliferation and induces apoptosis in many cancer cells including human colon cancer cell. A recent study shows that ZER can exert anti-metastatic effects via inhibition of FAK/Pi3k/NF-κB-uPA signaling pathway (Hosseini et al. 2019), reduce the proliferation of colon cancer cells (HCT116) by inhibiting the tumour necrosis factor alpha (TNF-alpha) (Singh et al. 2018) and enhancing the TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through the up-regulation of TRAIL death receptor DR4 and DR5 (Yodkeeree et al. 2009). Han et al. (2014) also reported that ZER can suppress interleukin-1β (IL-1β)-induced cell migration and invasion in human triple-negative breast cancer cells suggesting that ZER could be used to inhibit cell migration and invasion in cancer cells.

In reviewing the literature, there is still insufficient study on the effects of ZER in inhibiting cell migration and invasion towards colon cancer cells. Hence, this study aims to determine the effects of ZER on cell migration and invasion in colon cancer cell lines (HCT116).

MATERIALS AND METHODS

REAGENTS

Minimal essential medium with Earle’s balanced salts (MEM/EBSS) and fetal bovine serum (FBS) were purchased from GE Healthcare Life Sciences HyClone™ (Utah, USA), Roswell Park Memorial Institute medium (RPMI-1640) was purchased from Nacalai Tesque Inc. (Kyoto, Japan), dimethyl sulfoxide (DMSO) was purchased from Fisher BioReagents™ (Massachusetts, USA), 0.5% Trypsin-EDTA (10×) was purchased from Gibco® (Loughborough, USA), penicillin-streptomycin solution (100×) was purchased from BBI Life Sciences (Shanghai, China), trypsin blue solution (0.4%) was purchased from ScienCell™ Research Laboratories (Carlsbad, USA), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was purchased from Sigma Aldrich® (St. Louis, USA), and phosphate-buffered saline tablet was purchased from VWR® Life Science AMRESCO (Ohio, USA).

ZERUMBONE (ZER)

ZER compound in crystal form (99% purity) was kindly given by Assoc. Prof. Dr. Enoch Kumar Perimal from Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM). The ZER compound was prepared as previously described by Sulaiman et al. (2009), by slicing fresh rhizome of Z. zerumbet into pieces of 0.5-1 mm using a food processor. Then, essential oil from the plant was obtained through hydrodistillation. Hexane was used to enhance the extraction of essential oil. Pure ZER was obtained from the repetitive recrystallisation of the crude hydrodistillate.

The identity and purity of ZER were confirmed by nuclear magnetic resonance (NMR) spectrometry and high-performance liquid chromatography (HPLC).

CELL LINE

Human colon carcinoma cells (HCT116) and mouse embryonic fibroblast cells (NIH/3T3) were purchased from American Type Culture Collection (ATCC®) (ATCC accession no. HCT116 (CCL-247™) and NIH/3T3 (CRL-1658™), Manassas, USA). HCT116 and NIH/3T3 were cultured in MEM/EBSS and RPMI-1640, respectively, with 10% of FBS and 1% of penicillin-streptomycin solution (10×). The cells were grown in T75 tissue culture flask and incubated at 37 °C and 5% CO₂ incubator.

CYTOTOXICITY ASSAY

The analysis of cell viability was carried out by MTT cell-proliferation assay as previously described by Tolosa et al. (2015). The MTT assay is a tetrazolium salt reduction assay to assess cell metabolic activity. The cells (HCT116 and NIH/3T3) (1 10⁴ cells/well) were seeded in a 96-well plate and incubated for 24 h to allow the cells to attach to the plate. After 24 h, the medium was removed and the cells were treated with different concentrations of ZER (6.25, 12.5, 25, 50, 75, and 100 µg/mL). The respective concentrations were prepared by diluting the stock solution (100 mg/mL in DMSO) with the complete growth medium. The treated cells were incubated for three different time points (24, 48, and 72 h). The control group (untreated) was also included. After each incubation period, 20 µL of MTT solution (5 mg/mL) was added into each well and incubated for 3 h. Then, the medium containing MTT solution was discarded from the plate. The dark formazan crystals formed in the intact cells were dissolved by adding 100 µL of DMSO into each well. The absorbance was measured using a microplate reader (Tecan, infinite® M200, Männedorf, Switzerland) at the wavelength of 570 nm and reference wavelength of 630 nm. The MTT assay was performed in three replicates of three independent experiments. The
data obtained were tabulated and the percentage of cell viability for each concentration was calculated using the following formula:

\[
\text{Percentage of cell viability} = \frac{(\text{Absorbance sample})}{(\text{Absorbance control})} \times 100\%
\]

MORPHOLOGICAL STUDY
The HCT116 cells (1 × 10⁶ cells/well) were seeded into a 6-well plate and incubated for 24 h in the incubator at 37 °C with 5% of CO₂. Then, the cells were treated with three different selected concentrations (3, 6, and 9 µg/mL) of ZER for 24 h. The control group (untreated) was also included. After 24 h, the morphological changes for each concentration were observed under the inverted light microscope (Olympus Research Microscope, CH20i (Binocular Version), Tokyo, Japan) and compared to the control group.

SCRATCH ASSAY
The HCT116 cells (1 × 10⁶ cells/well) were seeded on a 6-well plate and incubated at 37 °C with 5% of CO₂ incubator for 24 h. After the cells attached and formed a confluent monolayer, a scratch was made using a sterile yellow pipette tip (200 µL pipette tip). The cells were treated with three different selected concentrations (3, 6, and 9 µg/mL) of ZER for 24 h. The pictures of initial wound gap at 0 and after 24 h were taken under the inverted light microscope (Olympus Research Microscope, CH20i (Binocular Version), Tokyo, Japan). The gap difference for each concentration was measured and analysed using ImageJ software (Bethesda, USA).

STATISTICAL ANALYSIS
IBM Statistical Package for the Social Sciences (SPSS) Statistics 24 software (New York, USA) was used to perform the statistical analysis. The results were presented as mean ± SEM (standard error of mean) of the mean of three independent experiments. The one-way analysis of variance (ANOVA) was used to analyse the results, followed by Tukey or Dunnett’s multiple comparison tests to determine the significant differences between the means. A p value of less than 0.05 (p <0.05) is considered to have significance.

RESULTS AND DISCUSSION

ZER INDUCED THE CYTOTOXICITY OF HUMAN COLON CANCER HCT116 CELLS
In the present study, the MTT assay was performed to evaluate the cytotoxicity of ZER on human colon cancer cells (HCT116). This assay assesses the viability of cells based on the reduction of a tetrazolium component (MTT) into an insoluble formazan product by the mitochondria of viable cells (Bahuguna et al. 2017). This method is quantitative and offers a sensitive detection of cell proliferation as it measures the growth rate of cells by virtue of a linear relationship between cell activity and absorbance (Mahajan et al. 2012).

The treatment with ZER at higher concentrations (25-100 µg/mL) significantly (p <0.05) reduced the cells viability of HCT116 cells (Figure 1(A)) compared to the untreated cells. The IC₅₀ value of HCT116 cells treated with ZER at 24, 48, and 72 h of incubation was 8.9, 18.0, and 21.3 µg/mL, respectively (Figure 1(B)). The results show that the IC₅₀ values were significantly increased in time-dependent manner, whereby the HCT116 cells treated with ZER at 24 h exhibited the lowest IC₅₀ value compared to those of at 48 and 72 h of incubation at p <0.05. Hence, three different selected concentrations of ZER were selected from the IC₅₀ values at 24 h of incubation for further analysis of cell morphology and scratch assay.

To evaluate the cytotoxic effect of ZER on non-cancerous cells, the MTT assay was also performed on mouse embryonic fibroblast cells (NIH/3T3). The NIH/3T3 cell was selected because it is the most commonly used cell for toxicity study (Rejmontová et al. 2016). The treatment of ZER at higher concentrations (12.5-100 µg/mL) significantly (p <0.05) reduced the cell viability of NIH/3T3 cell at three different incubation time compared to those of the untreated cells (Figure 2(A)). However, the NIH/3T3 cells treated with ZER at the concentration of 6.25 µg/mL shows 80% of cell viability. It is suggested that ZER significantly reduced cell proliferation in time-dependent manner. The result of IC₅₀ value of NIH/3T3 cells treated with ZER at 24, 48, and 72 h of incubation was 37.5, 15.3, and 15.0 µg/mL, respectively (Figure 2(B)). The IC₅₀ values of NIH/3T3 cells treated with ZER were significantly reduced in a time-dependent manner, while the NIH/3T3 cells treated with ZER at 24 h of incubation exhibited the highest IC₅₀ value at p <0.05.

Based on the results of cell viability, the IC₅₀ value of HCT116 cells at 24 h was 4-fold lower than the IC₅₀ value of NIH/3T3 cells. At the treatment of 9 µg/mL ZER (IC₅₀ of HCT116 cells; Figure 4), 74% of NIH/3T3 cells were found viable. This shows that the ZER at the concentration of 9 µg/mL has cytotoxic effect on HCT116 cells but less cytotoxic on the normal NIH/3T3 cancer cells as shown by the significant reduction of cell viability in HCT116 cells at 24 h of incubation.

It is postulated that ZER might exerts different mechanisms of cell death on the cancer and normal cells. Hoffman et al. (2002) showed that the ability of ZER in inducing high intracellular redox potential lead to inhibition of the cancer growth. However, the treatment of ZER on normal cells shows minimal effect on the growth of normal cells due to the differences in intracellular redox potential. In addition, the suppression of cancer cells by ZER was suggested by the inhibition
of carcinogen-induced NF-κB and NF-κB-regulated gene expression (Takada et al. 2005).

The increasing trend of the IC$_{50}$ value on HCT116 cells in time-dependent manner shows that ZER is effective in inhibiting the growth of cancer cells at shorter incubation period. In contrast, an opposite decreasing trend of the IC$_{50}$ value on NIH/3T3 cells was observed. Previous studies show that the IC$_{50}$ value of cancer cells (such as human breast adenocarcinoma, MDA-MB-231 and human colorectal cancer cell, COLO205) treated with ZER was decreased in a time-dependent manner (Hosseinpour et al. 2014; Thiyam & Narasu 2017). It can be hypothesised that the action of ZER on HCT116 cells is less effective as the treatment duration is increased. Therefore, the IC$_{50}$ value of HCT116 cells at 24 h of incubation was then selected for further study in morphology and scratch assays, as the IC$_{50}$ is potent in HCT116 cells but considerably less toxic towards the NIH/3T3 cells.

**ZER INHIBITED THE MIGRATION OF HUMANColon CANCER HCT116 CELLS**

The *in vitro* scratch assay was performed to evaluate the capability of ZER to inhibit the migration of HCT116 cells. This assay is a relatively cheap and easy method, where a gap was made by scratching and the movement of cells at the edge of the closing the gap was measured (Liang et al. 2007). Figure 3 shows the gap area of HCT116 cells before and after treated with different concentrations of ZER (3, 6, and 9 µg/mL) for 24 h of incubation. The treated cells show less migrated cells compared to the untreated cells (Figure 3). Based on the calculated gap area difference, ZER at lower concentration (3 µg/mL) shows the least migrated cells among the other treatment groups compared to that of the untreated cells (Figure 4). However, there was no significant difference (*p* >0.05) in the percentage of wound closure between the control (untreated cells) and the treated group. This may due to the limitation of the 2D scratch migration assay model as quantification of the scratch gap was less accurate compared to 3D migration assay which use porous membrane and quantification of migratory cells. Therefore, 3D migration assay and invasion assay which use extracellular matrix would be very beneficial to be done as future recommendation for this current study.

It is shown that ZER may inhibit the migration of colon cancer cells, which can be postulated by suppressing the cytokines which helps to regulate cell migration in cancer cells. Study done by Hosseini et al. (2019) shown that ZER could suppress cell migration and invasion in colon cancer cells by down-regulated the expression of NF-κB and uPA in FAK/P13K/AKT pathway. Han et al. (2014) show that ZER can potentially downregulate interleukin-8 (IL-8) and matrix metalloproteinase-3 (MMP-3) that are responsible in the migration and invasion of cancer cells. This also suggests that the effects of ZER in cell migration inhibition through the downregulation of CXCR4 protein expression (Sung et al. 2008) and suppressing the activity of NF-κB in blocking angiogenesis that is associated with metastasis (Shamoto et al. 2014). A recent study by Wang et al. (2019) shows that ZER treatment at 30 µM (6.5 µg/mL) contributed to the reduction of proliferation and migration in esophageal squamous cell carcinomas.

**CHARACTERISTICS OF APOPTOSIS IS OBSERVED ON HCT116 CELLS TREATED WITH ZER**

A morphological analysis was performed to evaluate the mode of cell death caused by ZER on HCT116 cells. Figure 5 shows the morphology of HCT116 cells before and after treated with different concentrations of ZER (3, 6, and 9 µg/mL) at 24 h of incubation. From Figure 5(A)-5(C), the cells treated with ZER at higher concentrations (6 and 9 µg/mL) show apoptotic characteristics such as shrinkage and cells detachment from the plate or floating cells compared to the untreated cells. At 24 h, the cells treated with 9 µg/mL of ZER show membrane blabbing as shown in the arrow in Figure 5(C) (40× magnification).

There are two main modes of cell death which are apoptosis and necrosis. Apoptosis is a natural system used by humans and animals to remove unwanted cells (Liu et al. 2018) and regulate cell death in response to stress as well as in normal growth process (Nikoletopoulou et al. 2013). This type of cell death exhibits cytoplasmic shrinkage, condensation of chromatin, plasma membrane blabbing, and presence of apoptotic bodies (Kerr et al. 1972). In contrast to apoptosis, necrosis is a pathological phenomenon resulting from exogenous stress (Liu et al. 2018), with the manifestations of organelles swelling and membrane rupture (Nikoletopoulou et al. 2013). Although these two mechanisms are very much different in nature, apoptosis is preferred as the mode of cell death because necrosis is often associated with inflammation and apoptosis has its molecular repair system (Kanduc et al. 2002). This study is important to investigate the mechanism of cell death on cancer cells by ZER compound ideally through apoptosis. As cancer cells can circumvent apoptosis through the modifications of protein and gene expressions (Fernald & Kurokawa 2013), it is suggested that the therapeutic effect can promote apoptosis in the cancer cells (Zhang et al. 2012). It is shown that ZER kills HCT116 cells through apoptotic pathway. Yodkeeree et al. (2009) has proven that the treatment with ZER can enhance TRAIL-induced apoptosis in HCT116 cells, induced by the up-regulation of TRAIL receptors. The mechanism of ZER in apoptosis is through downregulating anti-apoptotic and upregulating apoptotic proteins, to facilitate the permeabilisation of outer mitochondrial membrane and results in the release of cytochrome c (Hosseinpour et al. 2014).
FIGURE 1. Cytotoxicity of ZER on HCT116 cells (A) Percentages of cell viability of HCT116 cells treated with different concentrations of ZER at 24, 48, and 72 h of incubation, and (B) The IC_{50} value of ZER on HCT116 cells at three different incubation periods. Data were expressed as mean ± SEM of three independent experiments. Results were analysed using One-way ANOVA and Dunnett test. The significant mean difference of p-value less than 0.05, 0.01 and 0.001 is expressed as *, ** and ***, respectively, as compared to the control group (untreated cells).
FIGURE 2. Cytotoxicity of ZER on NIH/3T3 cells (A) Percentages of cell viability of NIH/3T3 cells treated with different concentrations of ZER at 24, 48, and 72 h of incubation, and (B) The IC_{50} value of ZER on NIH/3T3 cells at three different incubation periods. Data were expressed as mean ± SEM of three independent experiments. Results were analysed using One-way ANOVA and Dunnett test. The significant mean difference of p-value less than 0.05, 0.01 and 0.001 is expressed as *, ** and ***, respectively, as compared to the control group (untreated cells).
FIGURE 3. Scratch of HCT116 cells treated with different concentrations of ZER at 0 and 24 h incubation time (4× magnification)

FIGURE 4. Percentage of wound closure of HCT116 cells treated with different concentrations of ZER after 24 h incubation time in scratch assay. Data were expressed as mean ± SEM of two independent experiments. Results were analysed using One-way ANOVA and Dunnett test. The significant mean difference of p-value less than 0.05, 0.01 and 0.001 is expressed as *, ** and ***, respectively, as compared to the control group (untreated cells)
CONCLUSION

The preliminary findings in this study show that ZER can induce cytotoxicity and inhibits cell migration of human colon carcinoma cells (HCT116). Hence, the result suggests that ZER could be a promising agent to reduce the invasiveness of colon cancer cells. However, further studies on the mechanisms underlying the inhibition of colon cancer cells migration induce by ZER need to be carried out.

ACKNOWLEDGEMENTS

The authors would like to acknowledge all staff of the Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia for all the assistance and guidance throughout the research project. The authors declare that they have no competing interests.

REFERENCES

Abdalla, E.K., Adam, R., Bilehik, A.J., Jaeck, D., Vauthey, J.N., & Mahvi, D. 2006. Improving resectability of hepatic colorectal metastases: Expert consensus statement. Annals Surgical Oncology 13(10): 1271-1280.

Alhumaid, A., Al Yousef, Z., Bakhsh, H.A., AlGhamdi, S., & Aziz, M.A. 2018. Emerging paradigms in the treatment of liver metastases in colorectal cancer. Critical Reviews in Oncology/Hematology 132(2018): 39-50.

Bahuguna, A., Khan, I., Bajpai, V.K. & Kang, S.C. 2017. MTT assay to evaluate the cytotoxic potential of a drug. Bangladesh Journal of Pharmacology 12(2): 115-118.

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., & Jemal, A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 68(6): 394-424.

Cheng, Y., Yang, H., Chen, G. & Zhang, Z. 2013. Molecularly targeted drugs for metastatic colorectal cancer. Drug Design, Development and Therapy 7: 1315-1322.

Deorukhkar, A., Ahuja, N., Mercado, A.L., Diagaradjane, P., Raju, U., Patel, N., Mohindra, P., Diep, N., Guha, S., & Krishnan, S. 2015. Zerumbone increases oxidative stress in a thiol-dependent ROS-independent manner to increase DNA damage and sensitize colorectal cancer cells to radiation. Cancer Medicine 4(2): 278-292.

Fernald, K. & Kurokawa, M. 2013. Evading apoptosis in cancer. Trends in Cell Biology 23(12): 620-633.

Han, J., Bae, S.Y., Oh, S.J., Lee, J., Lee, J.H., Lee, H.C., Lee, S.K., Kil, W.H., Kim, S.W., Nam, S.J., Kim, S. & Lee, J.E. 2014. Zerumbone suppresses IL-1β-induced cell migration and invasion by inhibiting IL-8 and MMP-3 expression in human triple-negative breast cancer cells. Phytotherapy Research 28(11): 1654-1660.

Hoffman, A., Spetner, L.M. & Burke, M. 2002. Redox-regulated mechanism may account for zerumbone’s ability to suppress cancer-cell proliferation. Carcinogenesis 23(11): 1961-1962.
Hosseini, N., Khoshnazar, A., Saidijam, M., Azizi Jalilian, F., Najafi, R., Mahdavinezhad, A., Ezati, R., Sotanian, A. & Amini, R. 2019. Zerumbone suppress human colorectal cancer invasion and metastasis via modulation of FAK/P38/NFκB-aPA pathway. *Nutrition and Cancer* 71(1): 159-171.

Hosseinpour, M., Abdul, A.B., Rahman, H.S., Rasedee, A., Yeap, S.K., Ahmadi, N., Othman, H.H. & Chartrand, M.S. 2014. Comparison of apoptotic inducing effect of zerumbone and zerumbone-loaded nanostructured lipid carrier on human mammary adenocarcinoma MDA-MB-231 cell line. *Journal of Nanomaterials* 2014: 1-10.

Kerr, J.F.R., Wyllie, A.H. & Currie, A.R. 1972. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. *British Journal of Cancer* 26(4): 239-257.

Kanduc, D., Mittelman, A., Serpico, R., Sinigaglia, E., Sinha, A.A., Natale, C., Santacroce, R., Di Corcia, M.G., Luchese, A., Dini, L., Pani, P., Santacroce, S., Simone, S., Bucci, R. & Farber, E. 2002. Cell death: Apoptosis versus necrosis (review). *International Journal of Oncology* 21(1): 165-170.

Liang, C.C., Park, A.Y. & Guan, J.L. 2007. Scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. *Nature Protocols* 2(2): 329-333.

Liu, X., Yang, W., Guan, Z., Yu, W., Fan, B., Xu, N. & Liao, D.J. 2018. There are only four basic modes of cell death, although there are many ad-hoc variants adapted to different situations. *Cell & Bioscience* 8(1): 1-12.

Mahajan, S.D., Law, W.D., Aalinkeel, R., Reynolds, J., Nair, B.B., Yong, K.T., Roy, I., Prasad, P.N. & Schwartz, S.A. 2012. Nanoparticle-mediated targeted delivery of antiretrovirals to the brain. *Methods in Enzymology* 509: 41-60.

Manan, A.A., Tamin, N.S.I., Abdullah, N.S., Abidin, A.Z. & Wahab, M. 2016. *Malaysian National Cancer Registry Report 2007-2011*. Putrajaya: Ministry of Health, Malaysia. pp. 1-228.

Nikoletopoulou, V., Markaki, M., Palikaras, K. & Tavernarakis, N. 2013. Crosstalk between apoptosis, necrosis and autophagy. *Biochimica et Biophysica Acta* 1833(12): 3448-3459.

Rejmontová, P., Capáková, Z., Mikušová, N., Maráková, N., Kašpárková, V., Lehocky, M. & Humpholíček, P. 2016. Adhesion, proliferation and migration of NIH/3T3 cells on modified polyaniline surfaces. *International Journal of Molecular Sciences* 17(9): 1439.

Shamoto, T., Matsuo, Y., Shibata, T., Tsuibo, K., Nagasaki, T., Takahashi, H., Funahashi, H., Okada, Y. & Takeyama, H. 2014. Zerumbone inhibits angiogenesis by blocking NF-kB activity in pancreatic cancer. *Pancreas* 43(3): 396-404.

Siegel, R.L., Miller, K.D., Fedewa, S.A., Ahnen, D.J., Meester, R.G.S., Barzi, A. & Jemal, A. 2017. Colorectal cancer statistics, 2017. *CA: A Cancer Journal for Clinicians* 67(3): 177-193.

Singh, S.P., Nongalleima, K., Singh, N.I., Dooley, P., Singh, C.B., Singh, T.R. & Sahoo, D. 2018. Zerumbone reduces proliferation of HCT116 colon cancer cells by inhibition of TNF-alpha. *Scientific Reports* 8(1): Article ID: 4090.

Sulaiman, M.R., Perimal, E.K., Zakaria, Z.A., Mokhtar, F., Akhtar, M.N., Lajis, N.H. & Israf, D.A. 2009. Preliminary analysis of the antinociceptive activity of zerumbone. *Fitoterapia* 80(4): 230-232.

Sung, B., Jhurani, S., Ahn, K.S., Mastuo, Y., Yi, T., Guha, S., Liu, M. & Aggarwal, B.B. 2008. Zerumbone down-regulates chemokine receptor CXCR4 expression leading to inhibition of CXCL12-induced invasion of breast and pancreatic tumor cells. *Cancer Research* 68(21): 8938-8944.

Takada, Y., Murakami, A. & Aggarwal, B.B. 2005. Zerumbone abolishes NF-kB and IkB alpha kinase activation leading to suppression of antiapoptotic and metastatic gene expression, upregulation of apoptosis, and downregulation of invasion. *Oncogene* 24(46): 6957-6969.

Thiyam, R. & Narasu, M.L. 2017. Evaluation of cytotoxic and genotoxic effects of Zerumbone on colon adenocarcinoma COLO205 cells and human lymphocytes. *International Journal of Pharmacy and Pharmaceutical Sciences* 9(11): 92-96.

Tolosa, L., Donato, M.T. & Gómez-Lechón, M.J. 2015. General cytotoxicity assessment by means of the MTT assay. *Methods in Molecular Biology* 1250: 333-348.

Vassos, N. & Piso, P. 2018. Metastatic colorectal cancer to the peritoneum: Current treatment options. *Current Treatment Options in Oncology* 19(10): 1-18.

Wang, M., Niu, J., Gao, L., Gao, Y. & Gao, S. 2019. Zerumbone inhibits migration in ESCC via promoting Rac1 ubiquitination. *Biomedicine and Pharmacotherapy* 109: 2447-2455.

Yodkeeree, S., Sung, B., Limtrakul, P. & Aggarwal, B.B. 2009. Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species. *Cancer Research* 69(16): 6581-6589.

Zhang, S., Liu, Q., Liu, Y., Qiao, H. & Liu, Y. 2012. Zerumbone, a Southeast Asian ginger sesquiterpene, induced apoptosis of pancreatic carcinoma cells through p53 signaling pathway. *Evidence-based Complementary and Alternative Medicine* 2012: 1-8.

Tan Min Jien, Sitri Nur Parvin Ab Hamid, Nur Fariesha Md Hashim, Nurdin Armania, Hasni Idayu Saidi & Noraina Muhammad Zakuan*.

Department of Biomedical Sciences
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
43400 UPM Serdang, Selangor Darul Ehsan
Malaysia

Nurdin Armania
Department of UPM-MAKNA Cancer Research (CANRES)
Institute of Bioscience
Universiti Putra Malaysia
43400 UPM Serdang, Selangor Darul Ehsan
Malaysia

*Corresponding author; email: noraina@upm.edu.my

Accepted: 26 February 2020

Received: 9 December 2019
## TABLE S1. Percentage of cell viability of HCT116 cells treated with different concentrations of ZER at three different incubation periods (24, 48, and 72 h)

| Concentration (µg/mL) | Cell viability (%) |
|-----------------------|--------------------|
|                       | 24 h               | 48 h               | 72 h               |
| 0                     | 100.00 ± 0.00      | 100.00 ± 0.00      | 100.00 ± 0.00      |
| 6.25                  | 67.92 ± 2.26***    | 74.40 ± 5.59**     | 96.40 ± 19.19      |
| 12.5                  | 33.69 ± 2.26***    | 66.63 ± 7.35***    | 89.94 ± 20.70      |
| 25                    | 27.40 ± 2.32***    | 38.60 ± 1.91***    | 43.53 ± 6.73*      |
| 50                    | 18.86 ± 1.96***    | 28.14 ± 5.08***    | 23.43 ± 2.42**     |
| 75                    | 9.51 ± 2.47***     | 15.51 ± 2.06***    | 18.11 ± 3.03***    |
| 100                   | 7.06 ± 1.82***     | 7.74 ± 0.11***     | 14.83 ± 5.06***    |

Data were expressed as mean ± SEM of three independent experiments. Results were analysed using One-way ANOVA and Dunnett test. The significant mean difference of p-value less than 0.05, 0.01 and 0.001 is expressed as *, ** and ***, respectively, as compared to the control group (untreated cells).

## TABLE S2. IC_{50} values of ZER treated on HCT116 cells at three different incubation periods (24, 48, and 72 h)

| Incubation period (h) | IC_{50} (µg/mL) |
|-----------------------|-----------------|
| 24                    | 8.88 ± 0.25 a   |
| 48                    | 18.00 ± 1.15 b  |
| 72                    | 21.33 ± 3.48 b  |

Data were expressed as mean ± SEM of three independent experiments. Results were analysed using One-way ANOVA and Tukey HSD. The significant mean difference between groups (incubation period) of p-value less than 0.05 is expressed with different superscript letter a and b.
### TABLE S3. Percentage of cell viability of NIH/3T3 cells treated with different concentrations of ZER at three different incubation periods (24, 48, and 72 h)

| Concentration (µg/mL) | 24 h         | 48 h         | 72 h         |
|-----------------------|--------------|--------------|--------------|
| 0                     | 100.00 ± 0.00| 100.00 ± 0.00| 100.00 ± 0.00|
| 6.25                  | 88.80 ± 4.65 | 97.78 ± 1.45 | 83.41 ± 11.81|
| 12.5                  | 61.11 ± 1.06***| 59.80 ± 11.89***| 52.45 ± 7.46***|
| 25                    | 58.35 ± 1.00***| 29.44 ± 4.50***| 35.07 ± 5.13***|
| 50                    | 38.15 ± 4.61***| 8.78 ± 1.45*** | 11.96 ± 5.02***|
| 75                    | 9.89 ± 5.15***| 6.19 ± 1.15***| 6.62 ± 1.41***|
| 100                   | 3.64 ± 0.66***| 3.96 ± 1.15***| 3.94 ± 0.58***|

Data were expressed as mean ± SEM of three independent experiments. Results were analysed using One-way ANOVA and Dunnett test. The significant mean difference of *p*-value less than 0.05, 0.01 and 0.001 is expressed as *, ** and ***, respectively, as compared to the control group (untreated cells).